HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New York Supplement Firm Shut Down On GMP Violations Repeated Since 2010

Executive Summary

ABH Nature’s and its owner, Mohammed Jahirul Islam, agree to a consent decree recently barring them from distributing adulterated and misbranded supplements and unapproved and misbranded drugs and requiring remedial action before restarting production. FDA records indicate its s inspections of the facilities began in 2010 and at least one GMP violation found in later inspections was noted in the first.

You may also be interested in...



Shuttered US Supplement Firm Meets Recall Deadline, But Schumer Says FDA Late Cleaning Up Industry

While contract manufacturer ABH Nature' complied with consent decree, Sen. Chuck Schumer says FDA is late in enforcing against noncompliant firms across the supplement sector. Other recent consumer health recalls include more OTC ranitidine tablets due to the potential carcinogen NDMA found in the heartburn ingredient and four versions of Sure 48HR Anti-Perspirant & Deodorant with labeling errors.

US DoJ Has 'Key Focus' On Supplement Industry, Adds 6 Attorneys To Sector

"It is just common sense that there's going to be fraud where you have the combination of high growth, developing science, imported products or ingredients and limited oversight," says David Morrell, deputy assistant US attorney in DoJ'd Consumer Protection Branch. CPB is adhering to executive order President Trump made earlier in 2019 instructing federal agencies to enforced based on regulations, not on guidance.

Pataday Switch Appoval Dilates Eye Drop Category As Alcon's OTC Sales Driver

With Pataday Once Daily Relief (0.2% olopatadine) and Twice Daily (0.1%), Alcon adds allergy treatment to its lineup of OTC drops indicated for dry eye and redness. “Obviously, eye allergy will become a much bigger part of the portfolio for us,” says US vision care GM Sean Clark.

Topics

UsernamePublicRestriction

Register

RS149572

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel